Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD20 bispecific antibody DR-0201

A bispecific monoclonal antibody that targets the human tumor-associated antigen (TAA) CD20, with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD20 bispecific antibody DR-0201 targets and binds to CD20 on B-cell surface. This results in CD20-mediated signaling blockade and may induce phagocytosis of CD20-overexpressing cells by tissue-resident and trafficking myeloid cells, such as macrophages. This results in a depletion of pathogenic B cells. CD20 is overexpressed by certain cancer cell types and in various autoimmune diseases.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	bispecific myeloid cell engager DR-0201 MCE DR-0201
Code name:	DR 0201 DR-0201 DR0201

anti-CD20 bispecific antibody DR-0201

Search NCI's Drug Dictionary